Obeticholic acid for PBC
Integrity signals
Registry
Cites
Statistics
Claims the paper makes
Claims other papers make about this one
Each is checked against this paper’s own text: does it say what the citing paper says it does?
The rate of pruritus is positively correlated with OCA dosage (15% at 10 mg vs 38% at 50 mg).
“The rate of this adverse side-effect was found positively correlated with the dosage of OCA (15% in 10 mg vs. 38% in 50 mg)40.”
From Combined obeticholic acid and apoptosis inhibitor treatment alleviates liver fibrosis (2019) · cites this paper as [40]
Cites
A Placebo-Controlled Trial of Obeticholic Acid in Primary Biliary Cholangitis
Nevens, F., Andreone, P., Mazzella, G., Strasser, S. I., Bowlus, C., Invernizzi, P., Drenth, J. P. H., Pockros, P. J., Regula, J., Beuers, U., et al. (2016) · New England Journal of Medicine · doi:10.1056/nejmoa1509840 · Cited by 1,131 · see citing works
Flagged first, then by citations
Cited by
Sorted by citations
Combined obeticholic acid and apoptosis inhibitor treatment alleviates liver fibrosis
Zhou, J., Huang, N., Guo, Y., Cui, S., Ge, C., He, Q., Pan, X., Wang, G., Wang, H., & Hao, H. (2019) · Acta Pharmaceutica Sinica B · doi:10.1016/j.apsb.2018.11.004 · Cited by 99 · see citing works
Isotschimgine alleviates nonalcoholic steatohepatitis and fibrosis via FXR agonism in mice
Li, J., Liu, C., Zhou, Z., Dou, B., Huang, J.-W., Huang, L., Zheng, P.-Y., Fan, S., & Huang, C. (2021) · Phytotherapy Research · doi:10.1002/ptr.7055 · Cited by 14 · see citing works
Bile Acid Receptor Farnesoid X Receptor: A Novel Therapeutic Target for Metabolic Diseases
Fang, S. (2017) · Journal of Lipid and Atherosclerosis · doi:10.12997/jla.2017.6.1.1 · Cited by 12 · see citing works
Valluri, V. R., Katari, N. K., Khatri, C., Yadlapalli, S. S. R., Anand, K., Gundla, R., & Polagani, S. R. (2021) · Journal of Separation Science · doi:10.1002/jssc.202001050 · Cited by 5 · see citing works
AI-guided discovery and expansion of the human bile acid landscape
Yang, T., Yao, C., Kuang, J., Wang, L., 赵爱华, Zheng, D., Chen, Y., Liu, L., Zhang, Q., Chen, T., et al. (2026) · Cell Metabolism · doi:10.1016/j.cmet.2026.09.024
- Authors
- Thomas, H.
- Corresponding author
- Thomas, Hugh
- ORCID
- Thomas, Hugh
- Venue
- Nature Reviews Gastroenterology & Hepatology
- Published
- 2016-09-01
- Volume
- 13
- Issue
- 10
- Pages
- 559-559
- ISSN
- 1759-5045 (ISSN-L)
- 1759-5053
- OpenAlex
- W2507403604
- Cited by
- 5
- References
- 1
- Citations by year
- 2026: 1 · 2021: 2 · 2018: 1 · 2017: 1
- FWCI
- 0.48
- Type
- journal article
- Language
- en
- Open access
- closed
- Licence
- Locations
- Nature Reviews Gastroenterology & Hepatology (publishedVersion)
- PubMed (publishedVersion)
- Topics
- Health Sciences › Medicine › Hepatology › Liver Diseases and Immunity
- Health Sciences › Medicine › Oncology › Drug Transport and Resistance Mechanisms
- Health Sciences › Medicine › Surgery › Pediatric Hepatobiliary Diseases and Treatments
- Keywords
- obeticholic acid, primary biliary cirrhosis, farnesoid X receptor agonist, bile acid synthesis inhibition, cholestatic liver disease
- MeSH terms
- Chenodeoxycholic Acid, Humans, Liver Cirrhosis, Biliary, Ursodeoxycholic Acid
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
